Viagra Might Help To Reduce Metastasis

A recent study is drawing attention for a surprising reason: sildenafil, the active ingredient in Viagra, may do more than treat erectile dysfunction. Researchers reported evidence that it could also make it harder for cancer cells to spread, by interfering with the cells’ ability to access cholesterol, which appears to be important for metastasis.

The new work, published in Cancer Research, comes from scientists at the Weizmann Institute of Science and collaborators in the United States and Israel. Their proposed mechanism is notably different from the way sildenafil is usually understood. Instead of focusing only on its well-known effect on blood flow, the study suggests that blocking PDE5 increases cGMP and ultimately disrupts NPC1-mediated cholesterol trafficking inside cancer cells. In the researchers’ model, that cholesterol disruption appears to weaken the cells’ ability to break away from the primary tumor, survive in circulation, and colonize distant organs.

The evidence described in the article spans several levels. The team reports findings in mouse models, in human cancer cell cultures, and in a large analysis of long-term health records from Clalit Health Services, covering millions of patients over two decades. According to the article, cancer patients who took sildenafil had better survival outcomes, and the association looked even stronger when sildenafil was used together with statins. That combination is biologically plausible because statins reduce cholesterol production while sildenafil may reduce cholesterol availability inside cells.

The most important caveat is that the strongest human evidence described here is observational, which means it can show an association but cannot prove that sildenafil caused the better outcomes. Preclinical findings can be valuable and often guide new therapies, but they need proper clinical trials before changing medical practice. In other words, the study is interesting because it opens a new line of investigation, not because it establishes a new standard of care.

What makes the paper especially notable is the broader idea behind it: cancer behavior may be shaped not only by tumor genetics, but also by the patient’s metabolic state and by other medications already being taken for unrelated reasons.

For prostate cancer and other metastatic diseases, the topic is particularly relevant because spread to distant organs is often the critical event that determines prognosis.

Source.